Drug-induced agranulocytosis (clinical observation)

2021 ◽  
Vol 1 (30) ◽  
pp. 19-23
Author(s):  
N. A. Sokolova ◽  
L. V. Pozdnyakova ◽  
I. S. Tatarinova
Keyword(s):  
Adverse Effect ◽  
Clinical Observation ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Drug Induced ◽  
Life Threatening ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Antithyroid Agents ◽  
Stimulating Factor

The majority of agranulocytosis cases are caused by drugs, including nonsteroidal anti-inflammatory drugs, antibiotics, antithyroid agents, etc. Here, we report a case of severe agranulocytosis in a 67-year-old woman following nonsteroidal anti-inflammatory therapy which was successfully managed using recombinant human granulocyte colony-stimulating factor. Although metamizole, has been in use since 1922 in the management of postoperative pain, colic pain, cancer pain and migraine, agranulocytosis as a direct side effect of metamizole therapy has been rarely reported. It is important to keep in mind this rare but potentially life-threatening adverse effect of metamizole, when initiating therapy.

scholarly journals Severe Drug-Induced Agranulocytosis Successfully Treated with Recombinant Human Granulocyte Colony-Stimulating Factor

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Yohei Kubota ◽  
Toh Yoon Ezekiel Wong
Keyword(s):  
Adverse Events ◽  
Elderly Patients ◽  
Antibiotic Therapy ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Drug Induced ◽  
Serious Adverse Events ◽  
Concomitant Infection ◽  
Life Threatening ◽  
Stimulating Factor

When elderly patients are prescribed many different medications, the risk for developing serious adverse events should be kept in mind. One of these adverse events is agranulocytosis, which, although rare, can be life-threatening if left untreated. The majority of agranulocytosis cases are caused by drugs, including antibiotics. Here, we report a case of severe agranulocytosis in a 96-year-old woman following antibiotic therapy which was successfully managed using recombinant human granulocyte colony-stimulating factor (rhG-CSF) and the appropriate choice of antibiotics to treat her concomitant infection.

Non-chemotherapy drug-induced agranulocytosis in a tertiary hospital

2015 ◽  
Vol 35 (3) ◽  
pp. 244-250 ◽  
Author(s):  
R Navarro-Martínez ◽  
E Chover-Sierra ◽  
O Cauli
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Tertiary Hospital ◽  
Negative Association ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Drug Induced ◽  
Common Drug ◽  
Low Incidence ◽  
Stimulating Factor

Drug-induced agranulocytosis is a rare haematological disorder considered as severe adverse drug reaction. Due to its low incidence, the number of studies are low and the variability of clinical features and presentation in hospitalized patients is rarely described. Awe performed an observational, transversal and retrospective study in the haematology and toxicology unit in a tertiary hospital located in Spain (Valencia) (1996–2010) in order to assess its incidence, the drugs involved, the management and outcomes of drug-induced agranulocytosis. Twenty-one cases of agranulocytosis were retrieved. All of them presented severe and symptomatic agranulocytosis (fever and infection). The most common drug associated with drug-induced agranulocytosis was metamizole administration but other drugs belonging to different pharmacological classes as well (carbimazol, sulfasalazine, bisoprolol, itraconazole, amitryptiline, ketorolac and claritomicine+cefuroxime). No differences between sex and age were found in relationship with the manifestations or course of agranulocytosis. In contrast, a significantly negative association was found between age of patients and the percentage of increase in neutrophil count. Administration of human granulocyte colony-stimulating factor did not significantly enhance the recovery of the process or the restoration of leucocytes count, suggesting a limited utility in this type of agranulocytosis.

Atraumatic idiopathic splenic rupture induced by granulocyte-colony stimulating factor (G-CSF) for the treatment of pancytopenia, managed successfully by laparoscopic splenectomy

2020 ◽  
Vol 13 (4) ◽  
pp. e232411 ◽  
Author(s):  
Ugochukwu Chinyere Chinaka ◽  
Joshua Fultang ◽  
Jelizaveta Pereca ◽  
Abdulmajid Ali
Keyword(s):  
Laparoscopic Splenectomy ◽  
Splenic Rupture ◽  
University Hospital ◽  
Haemodynamic Instability ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Threatening Condition ◽  
Life Threatening ◽  
Stimulating Factor ◽  
Factor G

Splenic rupture is a potentially life-threatening condition and an uncommon short-term complication of granulocyte-colony stimulating factor (G-CSF) administration. It may present as acute abdominal pain or suddenly precipitously worsening anaemia with haemodynamic instability that requires urgent operative intervention for survival. We present a case of an atraumatic idiopathic splenic rupture in University Hospital, Ayr in a patient who received G-CSF treatment for chemotherapy-induced (methotrexate) pancytopenia and was successfully managed by laparoscopic splenectomy.

scholarly journals Granulocyte Colony-Stimulating Factor Treatment (G-CSF) of Antithyroid Drug-Induced Granulocytopenia

1994 ◽  
Vol 70 (5) ◽  
pp. 517-520
Author(s):  
Junichi TAJIRI ◽  
Shiro NOGUCHI ◽  
Mitsuo MORITA ◽  
Masaaki TAMARU ◽  
Nobuo MURAKAMI
Keyword(s):  
Antithyroid Drug ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Drug Induced ◽  
Stimulating Factor

scholarly journals Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Blood ◽  
2014 ◽  
Vol 123 (23) ◽  
pp. 3655-3663 ◽  
Author(s):  
Michael A. Pulsipher ◽  
Pintip Chitphakdithai ◽  
Brent R. Logan ◽  
Willis H. Navarro ◽  
John E. Levine ◽  
...  
Keyword(s):  
Adverse Events ◽  
Lower Risk ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Serious Adverse Events ◽  
Increased Risk ◽  
Key Points ◽  
Life Threatening ◽  
Stimulating Factor

Key Points BM donors have a threefold higher risk for life-threatening, serious unexpected, or chronic adverse events vs PBSC donors (0.99% vs 0.31%). Donors receiving granulocyte colony-stimulating factor for PBSC collection had no evidence of increased risk for cancer, autoimmune illness, and stroke.

Sign in / Sign up

Export Citation Format

Share Document